Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.
about
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1Implications of autophagy for vascular smooth muscle cell function and plasticityDrug-eluting stent: a review and updateNanoparticulate carriers for the treatment of coronary restenosisCurcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cellsRapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cellsRapamycin regulates the expression and activity of Krüppel-like transcription factor 2 in human umbilical vein endothelial cellsLocalized ultrasound enhances delivery of rapamycin from microbubbles to prevent smooth muscle proliferation.Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratiosPolylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes.In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation.The potential role of rapamycin in pediatric transplantation as observed from adult studies.Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.Rapamune does not attenuate high cholesterol-induced atherosclerosis in rabbits.Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activitySera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation.Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response.A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies.Exploiting novel molecular targets in gastrointestinal cancers.A journey in science: medical scientist in translation.Patterns of pulmonary complications associated with sirolimus.Stent development and local drug delivery.Sirolimus: a comprehensive review.Stent-based antirestenotic coatings (sirolimus/paclitaxel).Loss of canonical insulin signaling accelerates vascular smooth muscle cell proliferation and migration through changes in p27Kip1 regulation.Rapamycin inhibits anal carcinogenesis in two preclinical animal models.New developments in immunosuppressive therapy in renal transplantation.Rapamycin inhibits vascular smooth muscle cell migration.Coronary artery stents: evaluating new designs for contemporary percutaneous intervention.Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration.Therapeutic potential of active stent coating.Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.Targeting the cell cycle machinery for the treatment of cardiovascular disease.New approaches to preventing restenosis.TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent?Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.
P2860
Q24634783-04568952-FA92-4962-949C-3F962531A509Q26863422-B904260E-8851-45A4-BC8D-1F1DC88B3E50Q28219254-2C5E827E-DF40-4B2A-ABDD-8C45D6520BBCQ28220309-099B4045-8285-4287-9711-BA388EDFC5F3Q28303097-3021A4EF-CC10-4062-9AA6-B1AA2426EF3DQ28378927-17B324E4-BAAA-46CF-8CD2-CA631AAF691AQ28482627-15BAE8B7-6686-44A2-B7AC-C7A23F2C7D67Q30425418-D842E371-368F-4655-84FE-598EB2F21590Q31112412-CACAAD6B-2A48-49CB-BF2B-5AFCD432EC2DQ33391450-4A164C9A-6BBB-4C8E-A45F-022547F9094CQ33691133-57B05AB6-7989-4AD4-A9BD-96066232300FQ33732940-002653D9-C51A-4F19-AC22-A07DF9583BF6Q33757132-86372244-B326-4B06-886E-9DDBF667C37FQ33776274-FFD07458-DF02-42D1-8EF3-5C9DE8FC0609Q33806121-8C50D5AC-94FB-4756-A58B-846BF5899828Q33848041-9521A791-C73F-4433-A66D-8040D72DCEE9Q33889018-7571D57B-FC2B-4362-9DBF-04F4B8C1E679Q33939683-729F6E98-3599-4B3C-8507-E5E6F18E1E54Q34089207-8EF09845-6F9F-4E60-921B-F79B48C67D05Q34129012-97D0381B-23F5-4FA5-87C1-E08D22483CE9Q34294170-58401F7D-5397-4E0F-B88E-55026AF3D925Q34294786-5A5E34DD-882E-4E40-9AF4-908799694888Q34382777-32C23BB8-ED51-4792-A629-45C442883316Q34416243-2A75AD62-27A7-4A23-96B0-F4E353996973Q34446503-E5035070-91E6-4A8B-B7DB-09E28703C6B2Q34470332-05CC7D58-D2D7-4496-BC36-B0878CBDAEC7Q34515537-F2E02973-151F-47BA-A35F-D5B962CF7225Q34547687-66EA13FF-C590-4A61-9757-8F505EBB7854Q34566559-441F33CC-F72C-4723-9B9B-AFA92F33670FQ34679829-9DB3399A-3CD3-428C-982F-14E0BF15E57BQ34701373-E0F78282-B981-4F97-91AF-AC9AA0715C0CQ34736691-F4E62EC6-8218-4308-887D-18838C95E064Q34747489-70C71F45-AE2E-4990-A9C7-66535EE8A5ADQ34778754-0A7589DB-5866-4DB0-8544-2FED69D1437FQ35117070-D0D8EF96-3786-49A5-9BBB-ED0D90C63EF4Q35130521-F179722D-5AF7-4E5F-8B86-7BDB7673F7FDQ35164884-AE1C189B-6A67-4D9E-96F2-D7C587605698Q35190937-121909A0-F93F-4E39-96C2-A97C9C2D5CA7Q35645427-4D138D0B-EDDA-4B0E-964F-FF9816AAA2EBQ35938663-6760D660-FC7D-4C93-A6F2-D382B485C62A
P2860
Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@ast
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@en
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@nl
type
label
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@ast
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@en
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@nl
prefLabel
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@ast
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@en
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@nl
P2093
P356
P1433
P1476
Rapamycin-FKBP inhibits cell c ...... vascular smooth muscle cells.
@en
P2093
P304
P356
10.1161/01.RES.76.3.412
P577
1995-03-01T00:00:00Z